Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Protalix BioTherapeutics, Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.

Protalix Biotherapeutics develops and manufactures enzyme replacement therapies for rare diseases using their ProCellEx plant cell-based expression system.

Metric
Company Name	Protalix BioTherapeutics, Inc.	Axsome Therapeutics, Inc.
Symbol	PLX	AXSM
MSH ID	COM:PROTALIX	COM:AXSOME
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage		Post-IPO Equity
Employee Count	208	569
Website	protalix.com	axsome.com
LinkedIn
Founders

Metric
Market Cap	82.11M	3.92B
Enterprise Value
Monthly Web Traffic		7.82K
Web Traffic Growth		-0.74
Valuation
Raised Capital		225M

Metric
Revenue	65.49M	270.60M
Revenue (LTM)
Revenue (NTM)
Gross Profit	42.51M	237.70M
EBITDA	11.65M	-176.07M
Operating Income	10.46M	-182.91M
Net Income	8.31M	-239.24M
EPS	0.12	-5.27
Diluted EPS	0.09	-5.27
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.65	0.90
Operating Profit Margin	0.16	-0.86
EBITDA Margin	0.18	-0.65
Net Profit Margin	0.13	-0.88
Return on Equity	0.30	-1.12
Return on Assets	0.10	-0.41
Return on Capital Employed	0.27	-0.52

COM:PROTALIX

Protalix Biotherapeutics

Last Close

1.66

22/11 21:00

Market Cap

82.11M

Beta: -

Volume Today

545.62K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	9.94	-20.81
P/B Ratio	2.76	16.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.22	16.65
EV Multiple	10.46	-11.57

Metric
Days Sales Outstanding	51.26	128.09
Days Payables Outstanding	68.79	506.28
Days Inventory Outstanding	462.51	229.29
Operating Cycle	559.63	383.54
Cash Conversion Cycle	559.63	-229.81
Asset Turnover	0.78	0.53

Metric
Operating Cash Flow	-1.32M	-145.08M
Free Cash Flow	-2.47M	-145.66M
Cash Flow to Debt	0.22	-0.81
Operating Cash Flow/Sales	0.10	-0.54
Free Cash Flow Yield	-0.08	-0.03

Metric
Cash & Equivalents	23.63M	386.19M
Accounts Receivable	-428K	-57.12M
Inventory	19.05M	15.13M
Goodwill		12.04M
Debt to Capitalization	0.48	0.65
Debt to Assets	0.30	0.31
Current Ratio	1.67	4.46
Quick Ratio	1.09	3.46

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.04	0.24
R&D to Revenue	0.31	0.37
SG&A to Revenue	-0.66	0.44